World Health Organization recommends GLP-1 drugs for obesityWorld Health Organization recommends GLP-1 drugs for obesity
The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for patients. The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for […]
WHO recommends use of GLP-1 drugs for obesityWHO recommends use of GLP-1 drugs for obesity
WHO recommends use of GLP-1 drugs for obesity WHO recommends use of GLP-1 drugs for obesity
WHO issues guidance on GLP-1 drugs for obesityWHO issues guidance on GLP-1 drugs for obesity
The World Health Organization issued new guidelines recommending the use of GLP-1 drugs for adults with obesity and called for action on manufacturing and affordability. The World Health Organization issued new guidelines recommending the use of GLP-1 drugs for adults with obesity and called for action on manufacturing and affordability.
STAT+: Pharmalittle: We’re reading about a U.K.-U.S. tariff deal on drugs, a Lilly price cut for Zepbound, and moreSTAT+: Pharmalittle: We’re reading about a U.K.-U.S. tariff deal on drugs, a Lilly price cut for Zepbound, and more
Good morning, everyone, and nice to see you again after we took an extended holiday break. Of course, we are now playing a game of catch-up as we attempt to rifle through thousands of emails and digest the flood of news over the past several days. To cope, we are firing up the trusted coffee Read More
WHO backs GLP-1 treatments to tackle obesity epidemicWHO backs GLP-1 treatments to tackle obesity epidemic
A range of blockbuster weight-loss and diabetes drugs could help shift the trajectory of the global obesity epidemic, which affects over one billion people worldwide, the World Health Organization said Monday. A range of blockbuster weight-loss and diabetes drugs could help shift the trajectory of the global obesity epidemic, which affects over one billion people Read More
WHO recommends GLP-1 drugs for obesityWHO recommends GLP-1 drugs for obesity
The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the U.N. agency has historically framed obesity treatment. The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the Read More
Study reveals alarming number of invasive breast cancers in younger womenStudy reveals alarming number of invasive breast cancers in younger women
A study of data from seven outpatient facilities in the New York region found that 20–24% of all the breast cancers diagnosed during an 11-year period were found in women aged 18 to 49, according to research being presented at the annual meeting of the Radiological Society of North America (RSNA).
Risk Prediction Model for Heart Failure or Cardiomyopathy After Breast Cancer TreatmentRisk Prediction Model for Heart Failure or Cardiomyopathy After Breast Cancer Treatment
This longitudinal cohort study investigates whether a risk prediction model can estimate the 10-year risk of developing heart failure or cardiomyopathy in women receiving systemic treatment for invasive early-stage breast cancer.
Contraceptive Choices and Breast Cancer RiskContraceptive Choices and Breast Cancer Risk
This Viewpoint explores the injunction against taking hormonal contraceptives among premenopausal women at increased risk for breast cancer.
Do All Breast Cancer Survivors Need to See a Cardiologist?Do All Breast Cancer Survivors Need to See a Cardiologist?
Little is known about the contribution of breast cancer treatments to the long-term development of heart failure (HF) and/or cardiomyopathy (CM) in patients. For some treatments (eg, anthracyclines), specific recommendations for cardiac surveillance are based on the total cumulative dose received. For ERBB2 (formerly HER2)-targeted treatments, monitoring largely occurs in the setting of active treatment, with little guidance for subsequent surveillance or risk assessment. The expanding number of breast cancer survivors, with cardiovascular disease as an important competing cause of mortality, brings attention to understanding who is at risk for HF/CM after breast cancer treatments and whether preventive cardiac surveillance is warranted.